New drug cocktail aims to beat back aggressive throat cancer
NCT ID NCT07524413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or standard treatment. The study will measure how well the cancer responds and how long people live without the cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Becotatug Vedotin (MRG003) plus Pucotenlimab
- What this could lead to
- If successful, this could offer a more effective treatment option for people with high-risk nasopharyngeal cancer, potentially improving survival and reducing recurrence.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not yet known. The new drug combination may not be more effective than standard treatment and could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a baking soda rinse tame radiation mouth sores?
- New drug duo aims to keep advanced nasopharyngeal cancer in check
- Sharper radiation boost aims to tackle head and neck cancers that return
- Mouth rinse could ease painful radiation side effects for head and neck cancer patients
- New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment